AR035429A1 - Kit y composicion farmaceutica que contienen compuestos quimioterapeuticos - Google Patents
Kit y composicion farmaceutica que contienen compuestos quimioterapeuticosInfo
- Publication number
- AR035429A1 AR035429A1 ARP020100400A ARP020100400A AR035429A1 AR 035429 A1 AR035429 A1 AR 035429A1 AR P020100400 A ARP020100400 A AR P020100400A AR P020100400 A ARP020100400 A AR P020100400A AR 035429 A1 AR035429 A1 AR 035429A1
- Authority
- AR
- Argentina
- Prior art keywords
- active ingredient
- chemotherapeutic compounds
- approximately
- compounds
- paclitaxel
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000000973 chemotherapeutic effect Effects 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 4
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un kit que comprende: a) un primer componente que contiene una o más formas de dosificación unitaria orales de un ingrediente activo, conteniendo cada unidad aproximadamente 50 mg a aproximadamente 200 mg. del ingrediente activo, en donde el ingrediente activo es un compuesto seleccionado de la fórmula (1) o una sal o éster farmacéuticamente aceptable de dicho compuesto, en donde R1 se selecciona entre el grupo que consiste en -H, CH3 y -CH2OH y R2 es -CH3; y b) un segundo componente que contiene un frasco o una serie de frascos, conteniendo cada frasco una única dosis de solución inyectable o múltiples dosis de solución inyectable, conteniendo cada dosis como ingrediente activo aproximadamente 30 mg. a aproximadamente 400 mg de paclitaxel. Los compuestos de fórmula (1) son inhibidores del ciclo celular y tienen potente actividad terapéutica anticancerígena. El paclitaxel también es útil en terapias para el cáncer. La combinación de estos compuestos quimioterapéuticos es particularmente útil en el tratamiento de cánceres de mama, colon, recto, pulmón, útero y próstata. Composiciones farmacéuticas que comprenden dichos compuestos quimioterapéuticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26787401P | 2001-02-09 | 2001-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035429A1 true AR035429A1 (es) | 2004-05-26 |
Family
ID=23020488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100400A AR035429A1 (es) | 2001-02-09 | 2002-02-07 | Kit y composicion farmaceutica que contienen compuestos quimioterapeuticos |
| ARP140104645A AR098745A2 (es) | 2001-02-09 | 2014-12-12 | Composición, kit y uso de compuestos quimioterapéuticos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104645A AR098745A2 (es) | 2001-02-09 | 2014-12-12 | Composición, kit y uso de compuestos quimioterapéuticos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6548531B2 (es) |
| EP (1) | EP1359979B1 (es) |
| JP (1) | JP4128872B2 (es) |
| KR (1) | KR100542069B1 (es) |
| CN (1) | CN1265786C (es) |
| AR (2) | AR035429A1 (es) |
| AT (1) | ATE324145T1 (es) |
| AU (1) | AU2002246080B2 (es) |
| BR (1) | BR0206954A (es) |
| CA (1) | CA2435921C (es) |
| DE (1) | DE60210926T2 (es) |
| DK (1) | DK1359979T3 (es) |
| ES (1) | ES2261648T3 (es) |
| MX (1) | MXPA03007036A (es) |
| PT (1) | PT1359979E (es) |
| WO (1) | WO2002064214A2 (es) |
| ZA (1) | ZA200305967B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1383490B1 (en) * | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
| CA2447335C (en) * | 2001-05-15 | 2011-01-04 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of viral infections |
| US7001991B2 (en) * | 2001-05-15 | 2006-02-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of bioaffecting compounds for the treatment of cancer |
| WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
| US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| CN102985086A (zh) | 2010-03-29 | 2013-03-20 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| SI3541387T1 (sl) | 2016-11-15 | 2021-08-31 | Novartis Ag | Odmerek in režim za zaviralce interakcije HDM2-P53 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ227850A (en) | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
| US6080777A (en) * | 1992-01-31 | 2000-06-27 | The Trustees Of Columbia University In The City Of New York | Taxol as a radiation sensitizer |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| KR950702994A (ko) * | 1992-08-12 | 1995-08-23 | 로렌스 티. 웰츠 | 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol) |
| CN1127500C (zh) | 1998-03-17 | 2003-11-12 | 弗·哈夫曼-拉罗切有限公司 | 抑制细胞增殖的取代双吲哚基马来酰亚胺 |
| US6268398B1 (en) * | 1998-04-24 | 2001-07-31 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
| US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
-
2002
- 2002-01-23 US US10/055,451 patent/US6548531B2/en not_active Expired - Lifetime
- 2002-02-01 CA CA002435921A patent/CA2435921C/en not_active Expired - Lifetime
- 2002-02-01 JP JP2002564006A patent/JP4128872B2/ja not_active Expired - Lifetime
- 2002-02-01 WO PCT/EP2002/001042 patent/WO2002064214A2/en not_active Ceased
- 2002-02-01 BR BR0206954-7A patent/BR0206954A/pt not_active Application Discontinuation
- 2002-02-01 EP EP02714140A patent/EP1359979B1/en not_active Expired - Lifetime
- 2002-02-01 KR KR1020037010445A patent/KR100542069B1/ko not_active Expired - Lifetime
- 2002-02-01 AT AT02714140T patent/ATE324145T1/de active
- 2002-02-01 PT PT02714140T patent/PT1359979E/pt unknown
- 2002-02-01 DE DE60210926T patent/DE60210926T2/de not_active Expired - Lifetime
- 2002-02-01 MX MXPA03007036A patent/MXPA03007036A/es active IP Right Grant
- 2002-02-01 ES ES02714140T patent/ES2261648T3/es not_active Expired - Lifetime
- 2002-02-01 DK DK02714140T patent/DK1359979T3/da active
- 2002-02-01 AU AU2002246080A patent/AU2002246080B2/en not_active Expired
- 2002-02-01 CN CNB028047516A patent/CN1265786C/zh not_active Expired - Lifetime
- 2002-02-07 AR ARP020100400A patent/AR035429A1/es not_active Application Discontinuation
-
2003
- 2003-08-01 ZA ZA2003/05967A patent/ZA200305967B/en unknown
-
2014
- 2014-12-12 AR ARP140104645A patent/AR098745A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE324145T1 (de) | 2006-05-15 |
| CN1265786C (zh) | 2006-07-26 |
| KR100542069B1 (ko) | 2006-01-11 |
| EP1359979B1 (en) | 2006-04-26 |
| EP1359979A2 (en) | 2003-11-12 |
| CA2435921C (en) | 2009-12-22 |
| CA2435921A1 (en) | 2002-08-22 |
| ES2261648T3 (es) | 2006-11-16 |
| JP2004517961A (ja) | 2004-06-17 |
| MXPA03007036A (es) | 2003-11-18 |
| CN1491126A (zh) | 2004-04-21 |
| WO2002064214A3 (en) | 2003-05-30 |
| ZA200305967B (en) | 2005-01-26 |
| WO2002064214A2 (en) | 2002-08-22 |
| AR098745A2 (es) | 2016-06-08 |
| AU2002246080C1 (en) | 2002-08-28 |
| KR20040025894A (ko) | 2004-03-26 |
| US20020156118A1 (en) | 2002-10-24 |
| AU2002246080B2 (en) | 2006-08-10 |
| US6548531B2 (en) | 2003-04-15 |
| DE60210926D1 (de) | 2006-06-01 |
| BR0206954A (pt) | 2004-02-25 |
| PT1359979E (pt) | 2006-08-31 |
| WO2002064214A8 (en) | 2004-02-19 |
| DE60210926T2 (de) | 2007-01-11 |
| DK1359979T3 (da) | 2006-08-28 |
| JP4128872B2 (ja) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098745A2 (es) | Composición, kit y uso de compuestos quimioterapéuticos | |
| ES2543383T3 (es) | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano | |
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| JP2019135268A (ja) | 準最適に投与された化学化合物の治療的有効性 | |
| JP2021059579A (ja) | 癌を処置するための医薬組合せ | |
| RU2010147287A (ru) | Комбинированная композиция | |
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| SV2002000250A (es) | Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb | |
| UY28271A1 (es) | Compuestos químicos | |
| US20150005252A1 (en) | Combination therapy for the treatment of cancer | |
| SV2002000969A (es) | Composicion parenteral reconstituible | |
| ES2441593T3 (es) | Composiciones para estimular la actividad de terapias anticáncer | |
| UY28366A1 (es) | Compuestos químicos | |
| AR033390A1 (es) | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
| ES2267841T3 (es) | Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer. | |
| ES2278702T3 (es) | Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. | |
| ES2078838A1 (es) | Procedimiento para preparar una composicion a base de clozapina. | |
| WO2015153814A1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
| EA200600377A1 (ru) | Новая композиция | |
| CO5271647A1 (es) | Metodo para prevenir la diarrea | |
| ES2067206T3 (es) | Composiciones farmaceuticas conteniendo 3-amino-epsilon-caprolactamas para estimular el proceso de aprendizaje y la memoria. | |
| CN101605541A (zh) | 有效治疗化疗药物引起的周围神经毒性的吡咯并[1,2-a]咪唑二酮 | |
| AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |